Core Viewpoint - Marker Therapeutics, Inc. is actively participating in the H.C. Wainwright 3 Annual Cell Therapy Virtual Conference to present its advancements in T cell-based immunotherapies for treating hematological malignancies and solid tumors [1][2]. Company Overview - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, TX, focusing on next-generation T cell-based immunotherapies [4]. - The company was founded at Baylor College of Medicine and has conducted clinical trials involving over 200 patients, demonstrating that its autologous and allogeneic MAR-T cell products are well tolerated and show durable clinical responses [4]. - The company aims to introduce novel T cell therapies to the market while prioritizing financial resource preservation and operational excellence [4]. - Marker Therapeutics benefits from non-dilutive funding from U.S. state and federal agencies that support cancer research [4]. Event Details - Dr. Juan Vera, President and CEO of Marker Therapeutics, will present at the H.C. Wainwright 3 Annual Cell Therapy Virtual Conference on February 25, 2025, at 3:30 PM ET [2][3]. - The event will be held virtually, and registered participants can access the presentation through the event portal [3].

Core Viewpoint - Marker Therapeutics, Inc. has announced a private placement resulting in gross proceeds of $16.1 million to support the clinical advancement of its Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or are ineligible for it [1][2]. Financing Details - The financing will support the collection of additional clinical data for Marker’s lead clinical asset in lymphoma, MT-601 [3]. - The company is selling 5,031,250 shares of common stock at a purchase price of $3.20 per share, along with accompanying warrants [4]. - The pre-funded warrants will be exercisable at a price of $0.001 per share, while the accompanying warrants will have an exercise price of $4.03 per share [5]. Clinical Study Information - MT-601 is a multi-antigen recognizing (MAR) T cell product targeting six different tumor antigens upregulated in lymphoma cells [8]. - The APOLLO trial is a Phase 1, multicenter, open-label study designed to evaluate the safety and efficacy of MT-601 in participants with relapsed or refractory lymphoma [9]. - The trial aims to enroll approximately 30 participants across nine clinical sites in the United States during the dose escalation phase [9]. Company Overview - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, TX, focusing on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [12]. - The company’s unique T cell platform is supported by non-dilutive funding from U.S. state and federal agencies [12].

Core Insights - The APOLLO study demonstrates promising efficacy and safety for MT-601 in patients with relapsed lymphoma, with 78% of patients achieving objective response rates and 44.4% showing complete response [1][4][10] Safety - MT-601 infusion was well tolerated among all participants, with no cases of immune-effector cell associated neurotoxicity syndrome (ICANS) reported and only one instance of Grade 1 cytokine release syndrome (CRS) [3][11] - No dose limiting toxicities (DLTs) have been reported to date [3] Efficacy - In the first dose cohort, 7 out of 9 patients achieved objective responses (78%) at the first response assessment, with 4 patients demonstrating complete response (CR; 44.4%) [4][7] - Immunomonitoring data indicated that lymphodepletion enhanced the expansion and persistence of MAR-T cell clones in vivo [2] Follow-Up - Long-term follow-up data is available for three patients, with ongoing visits to assess the durability of responses [5][8] - The longest follow-up period recorded is 12 months for one patient, with two patients showing complete response (CR) and partial response (PR) at 6 months [8] Company Overview - Marker Therapeutics, Inc. is focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, with MT-601 being a multi-antigen recognizing (MAR) T cell product targeting six tumor antigens [13][16] - The APOLLO trial is a Phase 1, multicenter, open-label study evaluating the safety and efficacy of MT-601 in patients with relapsed or refractory lymphoma who have failed or are ineligible for anti-CD19 CAR-T cell therapy [14]

Core Viewpoint - Marker Therapeutics, Inc. has received a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the clinical investigation of its lead product MT-601 in patients with metastatic pancreatic cancer [1][5]. Group 1: Grant and Study Details - The CPRIT grant will support the Phase 1 PANACEA study, which evaluates the safety and tolerability of MT-601, a multi-tumor associated antigen-specific T cell product, in patients with metastatic pancreatic cancer [2]. - The company has received over $30 million in non-dilutive funding from various governmental institutions, including a recent $2 million grant from the NIH Small Business Innovation Research (SBIR) program [5][6]. Group 2: Product and Clinical Background - MT-601 is currently being studied for CD19-CAR relapsed lymphoma and has shown preliminary safety and efficacy with sustained objective responses in three participants [3]. - Previous studies have indicated that MT-601 can target multiple tumor-specific antigens, which may allow its application in solid tumors beyond lymphoma [4][9]. - A prior study at Baylor College of Medicine demonstrated favorable safety and durable cancer control in patients with pancreatic cancer treated with multiTAA-specific T cells [4]. Group 3: Company Overview - Marker Therapeutics is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [11]. - The company aims to introduce novel T cell therapies to the market while preserving financial resources and ensuring operational excellence [11].

Core Viewpoint - Marker Therapeutics, Inc. has received a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the clinical investigation of its lead asset MT-601 in patients with metastatic pancreatic cancer [1][5]. Funding and Grants - The CPRIT grant will support the Phase 1 PANACEA study evaluating the safety and tolerability of MT-601 in patients with metastatic pancreatic cancer [2]. - Including the CPRIT grant, the company has secured over $30 million in non-dilutive funding from various governmental institutions, including a recent $2 million grant from the NIH Small Business Innovation Research (SBIR) program [5][6]. Clinical Trials and Research - MT-601 is currently being studied in patients with CD19-CAR relapsed lymphoma, with preliminary safety and efficacy data showing sustained objective responses in three participants [3]. - Previous studies at Baylor College of Medicine indicated that multiTAA-specific T cells, similar to MT-601, demonstrated a favorable safety profile and durable cancer control in pancreatic cancer patients [4]. Product Overview - MT-601 is a multi-tumor associated antigen (multiTAA)-specific T cell product that targets six different tumor antigens upregulated in cancer cells [7]. - The product utilizes a non-genetically modified approach, which may offer easier and less expensive manufacturing with an improved safety profile compared to current engineered T cell therapies [8]. Company Background - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [9]. - The company aims to introduce novel T cell therapies to the market while prioritizing financial resource preservation and operational excellence [9].

Corporate Updates - Marker Therapeutics, Inc. is making significant progress in its Phase 1 APOLLO study of MT-601 for lymphoma patients who have relapsed after anti-CD19 CAR-T cell therapy or where CAR-T is not an option, with preliminary safety and efficacy data expected by the end of 2024 [2][3] - The company received two $2 million Small Business Innovation Research (SBIR) grants from the NIH to support the development of MT-601 in non-Hodgkin's lymphoma and pancreatic cancer [2][4] Program Updates - The Phase 1 APOLLO study is ongoing, with sustained objective responses observed in three participants, and no severe adverse effects reported [3] - The clinical investigation of MT-601 in metastatic pancreatic cancer is expected to start in 2025 [4] - Marker anticipates initiating the clinical program for MT-401-OTS in Acute Myeloid Leukemia or Myelodysplastic Syndrome in the first half of 2025 [5] Financial Highlights - As of September 30, 2024, Marker had cash and cash equivalents of $9 million, which is expected to fund operations into October 2025 [6] - Research and development expenses for Q3 2024 were $3.5 million, up from $2.0 million in Q3 2023, reflecting increased clinical trial activity [7] - General and administrative expenses decreased to $0.9 million in Q3 2024 from $1.4 million in Q3 2023 due to cost savings from a reorganization [7] - The net loss from continuing operations for Q3 2024 was $2.3 million, compared to $3.0 million in Q3 2023 [8] Revenue and Operating Expenses - Total revenues for Q3 2024 were $1.93 million, significantly higher than $0.26 million in Q3 2023, primarily due to increased grant income [15] - Total operating expenses for Q3 2024 were $4.33 million, compared to $3.46 million in Q3 2023 [15] T Cell Therapy Platform - Marker Therapeutics' multiTAA-specific T cell platform is a novel, non-genetically modified cell therapy that expands tumor-specific T cells capable of recognizing a broad range of tumor antigens, potentially offering improved safety and clinical benefits [9][10]

Revenue Generation - The company did not generate any revenue during the three months ended September 30, 2024 and 2023 from the sales or licensing of its product candidates [110]. - The company recognized $0.9 million and $0.2 million of revenue during the three months ended September 30, 2024 and 2023, respectively, associated with a $13.1 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) [111]. - The company recognized $0.02 million of revenue during the three months ended September 30, 2024 and 2023, respectively, associated with a $2.0 million grant from the FDA's Orphan Products Grant program [112]. - The company recognized $0.3 million of revenue during the three months ended September 30, 2024, associated with a $2.0 million grant from the National Institutes of Health SBIR program, while no revenue was recognized in the same period of 2023 [113]. - Grant income for the three months ended September 30, 2024, was $1,926,000, a 647% increase from $258,000 in the same period of 2023 [114]. - Total revenues for the three months ended September 30, 2024, were $1,926,000, reflecting a 647% increase compared to $258,000 in the prior year [114]. - Grant income for the nine months ended September 30, 2024, was $4,339,000, a 92% increase from $2,255,000 in the same period of 2023 [130]. - The company recorded $0.9 million and $2.4 million of grant income related to the CPRIT grant as revenue during the three and nine months ended September 30, 2024, respectively [146]. Expenses and Losses - The company incurred $1.2 million and $3.1 million in expenses related to services and manufacturing costs for the three and nine months ended September 30, 2024, respectively [101]. - Research and development expenses increased by 70% to $3,471,000 for the three months ended September 30, 2024, up from $2,045,000 in the same period of 2023 [117]. - General and administrative expenses decreased by 39% to $855,000 for the three months ended September 30, 2024, compared to $1,413,000 in the same period of 2023 [119]. - Total operating expenses for the three months ended September 30, 2024, were $4,326,000, a 25% increase from $3,458,000 in the same period of 2023 [114]. - Loss from operations for the three months ended September 30, 2024, was $(2,400,000), a 25% improvement from $(3,200,000) in the same period of 2023 [114]. - Total operating expenses for the nine months ended September 30, 2024, were $11,597,000, a 17% decrease from $13,898,000 in the same period of 2023 [130]. - Net loss from continuing operations for the nine months ended September 30, 2024, was $(6,895,000), a 39% improvement from $(11,305,000) in the same period of 2023 [130]. - Operating expenses for the three and nine months ended September 30, 2024, were $4.3 million and $11.6 million, respectively, compared to $3.5 million and $13.9 million in the prior year periods [152]. Grants and Funding - The company received a $2.0 million grant from the National Institutes of Health SBIR Program in August 2024 to support the advancement of MT-601 in patients with pancreatic cancer [107]. - The company received notice of a $2.0 million grant from the National Institutes of Health SBIR Program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma who have relapsed following anti-CD19 CAR T cell therapy [108]. - The company received a $2.0 million grant from the FDA's Orphan Products Grant program for the clinical investigation of MT-401, with $1.0 million received to date [147]. - The company has received a total of approximately $13.1 million from the CPRIT grant, with $9.7 million received to date [146]. Financial Position - Cash and cash equivalents as of September 30, 2024, were $9,000,000, down from $15,111,000 as of December 31, 2023 [137]. - As of September 30, 2024, the company had working capital of $7.4 million, down from $14.1 million as of December 31, 2023 [152]. - The company anticipates needing substantial additional funding for ongoing operations and may need to raise capital sooner than planned [152]. - The company has entered into an ATM Agreement allowing for the sale of up to $75.0 million in common stock, with net proceeds of approximately $37,000 from sales during the nine months ended September 30, 2024 [156]. Organizational Changes - The company implemented organizational changes in 2023, including a reduction in headcount and the appointment of Dr. Juan Vera as President and CEO [103]. - The company executed a one-for-ten reverse stock split on January 26, 2023, reducing the total number of authorized shares from 300 million to 30 million [106]. Market Conditions - High inflation and economic recession concerns have resulted in capital market volatility, potentially affecting the company's liquidity [155]. - The company plans to continue funding operations through equity and/or debt financing, which may dilute existing stockholders' interests [154].

Financial Performance - Total revenues for the three months ended June 30, 2024, were $1,169,000, representing a 53% increase from $763,000 in the same period of 2023[86]. - Total revenues for the six months ended June 30, 2024, were $2.4 million, a 21% increase from $2.0 million in the same period in 2023[93]. - Loss from operations improved by 44%, decreasing to $(2,308,000) in Q2 2024 from $(4,134,000) in Q2 2023[86]. - The net loss from continuing operations decreased by 45% to $4.6 million for the six months ended June 30, 2024, from $8.3 million in the same period in 2023[93]. Operating Expenses - Operating expenses decreased by 29% to $3,477,000 in Q2 2024 from $4,897,000 in Q2 2023, with general and administrative expenses dropping by 55%[86]. - Operating expenses for the three months ended June 30, 2024, were $3.5 million, a decrease from $4.9 million in the same period in 2023[89]. - Total operating expenses for the six months ended June 30, 2024, were $7.3 million, down 30% from $10.4 million in the same period in 2023[96]. - Operating expenses for the three and six months ended June 30, 2024 were $3.4 million and $7.2 million, respectively, compared to $4.9 million and $10.4 million in the prior year periods, indicating a decrease of approximately 30.6% and 30.6%[111]. Interest Income - Interest income increased significantly by 229% to $115,000 in Q2 2024 compared to $35,000 in Q2 2023[86]. - Interest income increased by 127% to $272,000 for the six months ended June 30, 2024, compared to $120,000 in the same period in 2023[93]. Grants and Revenue Recognition - The company recognized $0.7 million in revenue from the CPRIT grant for both Q2 2024 and Q2 2023, with additional revenue from FDA and NIH grants totaling $0.2 million and $0.2 million respectively in Q2 2024[87][88]. - The company has received a total of $13.1 million in grants from CPRIT to support the clinical investigation of MT-401, with $9.7 million received to date[107]. - The company recognizes revenue from grant income when qualifying costs are incurred, reflecting its critical accounting estimates[117]. Cash and Liquidity - Cash and cash equivalents as of June 30, 2024, were $7.8 million, down from $15.1 million as of December 31, 2023[101]. - As of June 30, 2024, the company had working capital of $9.7 million, down from $14.1 million as of December 31, 2023[111]. - The company expects its cash and cash equivalents will fund operations into the fourth quarter of 2025[100]. - The company expects its cash and cash equivalents as of June 30, 2024 to fund operating expenses and capital expenditures into Q4 2025, although this estimate is subject to change[111]. Organizational Changes - Organizational changes in 2023 included a reduction in headcount and the appointment of Dr. Juan Vera as President and CEO[82]. Product Development - The company is advancing two product candidates for clinical indications: MT-601 for lymphoma and pancreatic cancer, and MT-401-OTS for various indications[72]. Financing and Market Conditions - The company plans to fund operations and capital needs through equity and/or debt financing, which may dilute existing stockholders' ownership[113]. - High inflation and economic recession concerns have led to capital market volatility, potentially affecting the company's liquidity[114]. - The company may need additional funds sooner than planned to meet operational needs and capital requirements for product development and commercialization[111]. - The company is unable to estimate the actual amounts necessary for the development and commercialization of product candidates due to the early stages of clinical development[112]. Stock and Shareholder Matters - A reverse stock split of 1-for-10 was executed on January 26, 2023, reducing the total number of authorized shares from 300 million to 30 million[84]. - The company sold 8,178 shares under the ATM Agreement during the six months ended June 30, 2024, resulting in net proceeds of approximately $37,000 after agent commissions[115]. - The company has the right to sell up to $25 million of shares to Lincoln Park Capital Fund, LLC, but terminated this Purchase Agreement effective March 1, 2024[116].

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity syndrome (ICANS) Marker Therapeutics to receive $2 million funding from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma HOUSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) ...

[First Quarter 2024 Business and Clinical Update](index=1&type=section&id=First%20Quarter%202024%20Business%20and%20Clinical%20Update) Marker Therapeutics provides an overview of its Q1 2024 business and clinical advancements, highlighting promising MT-601 lymphoma data and program milestones [First Quarter 2024 Highlights](index=1&type=section&id=First%20Quarter%202024%20Highlights) Marker Therapeutics reported promising preliminary Phase 1 APOLLO study data for MT-601 in lymphoma, showing sustained objective responses and securing the nonproprietary name "neldaleucel" - Preliminary safety and efficacy with **sustained objective responses** were observed in lymphoma patients treated with MT-601 in the Phase 1 APOLLO study[1](index=1&type=chunk) - A study participant with Non-Hodgkin's Lymphoma, who had relapsed within 90 days of anti-CD19 CAR T cell therapy, remains in **complete response nine months** after receiving MT-601 treatment[1](index=1&type=chunk)[2](index=2&type=chunk) - MT-601 received the approved nonproprietary name "**neldaleucel**" from the United States Adopted Name (USAN) council and the International Nonproprietary Names (INN) expert committee[1](index=1&type=chunk)[2](index=2&type=chunk) [Program Updates & Expected Milestones](index=2&type=section&id=PROGRAM%20UPDATES%20%26%20EXPECTED%20MILESTONES) The company is prioritizing the MT-601 lymphoma program, while the pancreatic cancer program awaits funding and the AML program shifts to an "Off-the-Shelf" approach [MT-601 (Lymphoma)](index=2&type=section&id=MT-601%20(Lymphoma)) The MT-601 lymphoma program, selected as the lead, shows objective responses in all three initial patients with plans for further enrollment and data reporting - The Phase 1 multicenter APOLLO trial for MT-601 was selected as the **lead program** for patients with lymphoma who relapsed or are ineligible for anti-CD19 CAR T cell therapies[3](index=3&type=chunk) - **All three patients** treated at City of Hope demonstrated **objective responses** (two complete, one partial) and the treatment was well-tolerated with no significant treatment-related adverse events like cytokine release syndrome or neurotoxicity[5](index=5&type=chunk) - The company plans to enroll additional patients in the APOLLO trial and report further data in the **second half of 2024**[5](index=5&type=chunk) [MT-601 (Pancreatic)](index=2&type=section&id=MT-601%20(Pancreatic)) The MT-601 pancreatic cancer program has FDA IND clearance, with clinical advancement contingent on securing additional non-dilutive funding - The FDA has cleared the Investigational New Drug (**IND**) application for a Phase 1 trial of MT-601 in patients with metastatic pancreatic cancer[5](index=5&type=chunk) - Clinical advancement for the pancreatic cancer program is **contingent upon securing additional financial support** through non-dilutive grant activities[5](index=5&type=chunk) [MT-401-OTS (Acute Myeloid Leukemia or Myelodysplastic Syndrome)](index=2&type=section&id=MT-401-OTS%20(Acute%20Myeloid%20Leukemia%20or%20Myelodysplastic%20Syndrome)) The AML program has shifted to an "Off-the-Shelf" MT-401-OTS product, which has received IND and Orphan Drug Designations, with clinical trials expected in H2 2024 - The company has shifted its AML program to focus on an "**Off-the-Shelf**" (**OTS**) **product, MT-401-OTS**, discontinuing the patient-specific approach to streamline resources[4](index=4&type=chunk) - MT-401-OTS has been granted an **IND** by the U.S. FDA and received **Orphan Drug Designation** from both the EMA and FDA[10](index=10&type=chunk) - Clinical program initiation for MT-401-OTS is anticipated in the **second half of 2024**, supported by **$2 million** in non-dilutive funding from an NIH SBIR grant[10](index=10&type=chunk) [First Quarter 2024 Financial Results](index=3&type=section&id=First%20Quarter%202024%20Financial%20Results) Marker Therapeutics reports its Q1 2024 financial performance, detailing cash position, reduced operating expenses, and a significantly lower net loss [Financial Highlights Summary](index=3&type=section&id=FIRST%20QUARTER%202024%20FINANCIAL%20HIGHLIGHTS) Marker Therapeutics held **$11.3 million** in cash as of March 31, 2024, projecting funding into Q4 2025, with reduced R&D and G&A expenses leading to a lower **$2.4 million** net loss - Cash and cash equivalents stood at **$11.3 million** as of March 31, 2024, which is expected to fund operating expenses into the **fourth quarter of 2025**[6](index=6&type=chunk) Q1 2024 vs. Q1 2023 Financial Comparison | Financial Metric | Q1 2024 ($) | Q1 2023 ($) | | :--- | :--- | :--- | | R&D Expenses | $2.6 million | $3.4 million | | G&A Expenses | $1.2 million | $2.2 million | | Net Loss | $2.4 million | $4.9 million | [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2024, total assets were **$14.1 million**, a decrease from **$17.1 million** at year-end 2023, with total liabilities at **$2.3 million** and stockholders' equity at **$11.8 million** Balance Sheet Summary (Unaudited) | Balance Sheet Item | March 31, 2024 ($) | December 31, 2023 ($) | | :--- | :--- | :--- | | Cash and cash equivalents | $11,323,428 | $15,111,450 | | Total Assets | $14,091,899 | $17,127,391 | | Total Liabilities | $2,303,665 | $3,074,848 | | Total Stockholders' Equity | $11,788,234 | $14,052,543 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) In Q1 2024, Marker Therapeutics reported **$1.24 million** in grant income and significantly reduced operating expenses to **$3.8 million**, resulting in a net loss of **$2.4 million**, or **($0.27)** per share Statement of Operations Summary (Unaudited, For the Three Months Ended March 31) | Income Statement Item | 2024 ($) | 2023 ($) | | :--- | :--- | :--- | | Grant income | $1,244,061 | $1,234,336 | | Total operating expenses | $3,793,078 | $5,543,815 | | Loss from operations | ($2,549,017) | ($4,309,479) | | **Net loss** | **($2,392,822)** | **($4,967,576)** | | **Net loss per share, basic and diluted** | **($0.27)** | **($0.57)** | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2024, the company utilized **$3.8 million** in cash for operating activities, resulting in a **$3.8 million** decrease in cash and equivalents, ending the period at **$11.3 million** Statement of Cash Flows Summary (Unaudited, For the Three Months Ended March 31) | Cash Flow Item | 2024 ($) | 2023 ($) | | :--- | :--- | :--- | | Net cash used in operating activities | ($3,837,118) | ($5,888,295) | | Net cash provided by financing activities | $49,096 | $619,974 | | Net decrease in cash and cash equivalents | ($3,788,022) | ($5,380,929) | | **Cash and cash equivalents at end of period** | **$11,323,428** | **$6,401,243** | [About Marker Therapeutics](index=3&type=section&id=About%20Marker%20Therapeutics) Marker Therapeutics is a clinical-stage immuno-oncology company leveraging its multiTAA-specific T cell platform for cancer therapies, emphasizing financial discipline and non-dilutive funding [About multiTAA-specific T cells](index=3&type=section&id=About%20multiTAA-specific%20T%20cells) Marker Therapeutics' core multiTAA-specific T cell platform is a non-genetically modified cell therapy designed to recognize a broad range of tumor antigens, offering potential advantages over engineered CAR-T and TCR therapies - The **multiTAA-specific T cell platform** is a novel, **non-genetically modified cell therapy** approach that expands tumor-specific T cells capable of recognizing a broad range of tumor antigens[8](index=8&type=chunk) - Marker believes its product candidates will be **easier and less expensive to manufacture**, with **reduced toxicities**, compared to current engineered CAR-T and TCR-based approaches[8](index=8&type=chunk) [Company Overview](index=3&type=section&id=Company%20Overview) Marker Therapeutics is a Houston-based clinical-stage immuno-oncology company developing T cell immunotherapies for cancers, prioritizing financial discipline and leveraging non-dilutive government funding - Marker Therapeutics is a **clinical-stage immuno-oncology company** focused on developing **T cell-based immunotherapies** for hematological malignancies and solid tumors[9](index=9&type=chunk) - The company prioritizes the preservation of financial resources and operational excellence, and its platform is supported by **non-dilutive funding** from U.S. state and federal agencies[9](index=9&type=chunk)